Bilix key facts
as of Oct 2026- Developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation and oxidative stress.
- Bilix is valued at approximately $28.1M as of Oct 2026 (last reported valuation).
- It has raised $10.0M; the latest was Later Stage VC ($19.5M) in Dec 2025.
- Notable investors include iM Investment Partners, BiiG WAVE, Magna Investment (Seoul), Alpen Route Asset Management, DS Capital — 15 tracked in total.
- Status: Privately Held (backing).
Bilix's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch Bilix: the Monday email on marks, rounds and moves
Bilix funding rounds
No funding rounds for Bilix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Bilix
15+Bilix valuation
Bilix's last reported valuation was $28.1 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
Bilix investors
15 investors are on record for Bilix, including iM Investment Partners, BiiG WAVE, Magna Investment (Seoul) and Alpen Route Asset Management.
About Bilix
Developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation and oxidative stress. The company offers a nanoparticle-based therapy with demonstrated safety in early trials and a targeted application for cardiac surgery-associated acute kidney injury, enabling pharmaceutical companies, clinicians, and healthcare providers to address organ damage caused by interrupted and restored blood flow, improve surgical outcomes, and reduce the long-term burden of acute kidney injury.
- Sector
- Healthcare
- HQ
- Yongin, South Korea
- Founded
- 2018
- Employees
- 12
- Website
- bilix.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.